Georgetown Lombardi Comprehensive Cancer Center Redesignated by National Cancer Institute

MedStar Georgetown University Hospital is proud to announce that the National Cancer Institute (NCI) has redesignated Georgetown Lombardi Comprehensive Cancer Center as a “comprehensive cancer center.” Georgetown Lombardi has now maintained this designation for the last 21 years and is currently one of only 41 comprehensive cancer centers in the United States.

October 9, 2014

Patients Benefit From Access To Oncology’s Leading Experts, Research And Community Outreach

MedStar Georgetown University Hospital is proud to announce that the National Cancer Institute (NCI) has redesignated Georgetown Lombardi Comprehensive Cancer Center as a “comprehensive cancer center.” Georgetown Lombardi has now maintained this designation for the last 21 years and is currently one of only 41 comprehensive cancer centers in the United States.

For cancer patients in the Washington, DC area, this provides confirmation that Georgetown Lombardi is the cancer center of choice, with well-coordinated diagnostics, treatments, clinical trials and research that are on the leading edge of medical science.

“Our designation as a comprehensive cancer center has a direct effect on our community,” explains Dr. Louis M. Weiner, director of Georgetown Lombardi. “Most top oncologists choose to practice at comprehensive cancer centers like ours because it allows them to pursue research that can directly benefit our patients through clinical trials or laboratory discoveries. When someone has cancer, they want the best doctors and cutting-edge treatments. That’s what Georgetown Lombardi offers.”

Technologies like CyberKnife that MedStar Georgetown has used to treat inoperable cancers since 2002 and a proton therapy program to open in 2015 are examples of the cutting-edge care available to patients in the region. MedStar Georgetown will become one of only 13 facilities in the United States to offer the highly advanced proton therapy that precisely targets and destroys cancer cells, sparing healthy cells, reducing side effects, improving patients’ cure rates and reducing the chances of secondary cancers later in life. Proton therapy will be used to treat adults as well as children with cancer.

“The renewal of the National Cancer Institute designation recognizes the invaluable asset the Georgetown Lombardi Comprehensive Cancer Center is to the community we serve both locally and nationally,” said Dr. Richard Goldberg, president of MedStar Georgetown University Hospital and senior vice president of MedStar Health. “As Lombardi’s clinical partner in providing world-class cancer treatment and care to patients across the region, this redesignation further demonstrates the strength of our joint activities in research, community education and outreach. By linking scientific discovery and expert and compassionate patient care, MedStar and Georgetown Lombardi will continue to prevent, treat and help cure cancers.”

Georgetown Lombardi operates two offsite facilities - the Capital Breast Care Center and the Office of Minority Health and Health Disparities Research, both located in Southeast DC that anchor its community-based screening and research efforts among underserved populations. The federal NCI designation as a comprehensive cancer center indicates that Georgetown Lombardi excels in laboratory science, clinical research and population-based programs, along with robust translational research that bridges these areas. It also demonstrates expansive public education and outreach capabilities, which focus on the Washington, DC community.

“This NCI redesignation means that our patients continue to have access to cutting edge treatments, the latest clinical trials and that their care here at MedStar Georgetown is truly patient-centered and comprehensive,” said Dr. John Marshall, chief, Hematology and Oncology at MedStar Georgetown. “Part of being comprehensive means we have multidisciplinary disease teams dedicated to treating their specific cancer. Our faculty members are recognized as national and global leaders in their fields and are an unmatched resource for the patients in our community. Whether one is faced with breast, lung, pancreas, stomach, colorectal or urologic cancer, leukemia, lymphoma, head and neck cancers, sarcomas or pediatric cancers, we provide the team with the most focused expertise in our region. By combining the knowledge of an oncologist, a cancer surgeon, radiation oncologist, nurse navigator and social worker with a variety of support groups and programs like art and music therapy, our patients have all their needs addressed during one of the most difficult times of their lives.”

As Georgetown Lombardi continues to advance cancer care for patients throughout the area, its focus will remain in four specific areas of excellence: cancer prevention and control, breast cancer, experimental therapeutics and molecular oncology. The area of cancer prevention and control received a particularly high rating from NCI reviewers. This program conducts population-based and translational research across the spectrum of cancer control, ranging from early detection to lifestyle intervention to survivorship issues.

Media Contact

Marianne Worley
[email protected]
703-558-1287

Back to Top